iCardiac

📍 Philadelphia, United States🗓 Founded 1997👥 21 employees💰 Last funded Mar 2014
Biotechnology Research🌐 ert.com
Website LinkedIn
iCardiac Technologies was acquired by ERT in December, 2017. ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that our customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, we balance knowledge of what works with a vision for what’s next, so we can adapt without compromising standards. Powered by the company’s EXPERT® technology platform, our solutions enhance trial oversight, enable site optimization, increase patient engagement, and measure the efficacy of new clinical treatments while ensuring patient safety. Over the past four years, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs, and CROs have relied on ERT solutions in over 10,000 studies spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence. Follow ERT and learn how you can accelerate clinical development with confidence.
4
Total investors
0
Early stage
0
Mid stage
2
Late stage
1997
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2006–2014 · investors recorded per year
200622013120141
Recent (last 2y)Earlier
Frequently asked questions
Who invested in iCardiac?
iCardiac has 4 investors on record on gritt.io and 2 late-stage investors.
When did iCardiac last raise funding?
The most recent investment in iCardiac recorded on gritt.io was in March 2014.
When was iCardiac founded?
iCardiac was founded in 1997.
What industry is iCardiac in?
iCardiac operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is iCardiac based?
iCardiac is headquartered in Philadelphia, United States.